
Cue Biopharma, Inc. (NASDAQ:CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.
This IND acceptance enables the dose escalation of Phase 1 trial to start dosing at 1 mg/kg, supported by the safety and tolerability data from the CUE-101 (the first biologic from the CUE-100 series) trial.